JP2011225596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011225596A5 JP2011225596A5 JP2011144522A JP2011144522A JP2011225596A5 JP 2011225596 A5 JP2011225596 A5 JP 2011225596A5 JP 2011144522 A JP2011144522 A JP 2011144522A JP 2011144522 A JP2011144522 A JP 2011144522A JP 2011225596 A5 JP2011225596 A5 JP 2011225596A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human beta
- beta defensin
- amino acid
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (16)
- 炎症性腸疾患の治療における、経口投与のための医薬組成物であって、ヒト・ベータ・ディフェンシンを含む前記組成物。
- 前記ヒト・ベータ・ディフェンシンが、０．００１ｍｇ／ｋｇ体重〜１０ｍｇ／ｋｇ体重、好ましくは０．０１ｍｇ／ｋｇ体重〜１０ｍｇ／ｋｇ体重の一日用量で投与される、請求項１に記載の組成物。
- 前記ヒト・ベータ・ディフェンシンが、配列番号１、配列番号２、配列番号３、又は配列番号４のアミノ酸配列と、少なくとも８０％、好ましくは少なくとも８５％、より好ましくは少なくとも９０％、そして最も好ましくは少なくとも９５％の同一性を有する、請求項１又は２に記載の組成物。
- 前記ヒト・ベータ・ディフェンシンが、ヒト・ベータ・ディフェンシン１、ヒト・ベータ・ディフェンシン２、ヒト・ベータ・ディフェンシン３、又はヒト・ベータ・ディフェンシン４である、請求項１〜３のいずれか一項に記載の組成物。
- 前記ヒト・ベータ・ディフェンシンが、配列番号２のアミノ酸配列と少なくとも８０％の同一性を有する、請求項１〜４のいずれか一項に記載の組成物。
- 前記ヒト・ベータ・ディフェンシンが、配列番号２のアミノ酸配列と少なくとも８５％の同一性を有する、請求項１〜５のいずれか一項に記載の組成物。
- 前記ヒト・ベータ・ディフェンシンが、配列番号２のアミノ酸配列と少なくとも９０％の同一性を有する、請求項１〜５のいずれか一項に記載の組成物。
- 前記ヒト・ベータ・ディフェンシンが、配列番号２のアミノ酸配列と少なくとも９５％の同一性を有する、請求項１〜５のいずれか一項に記載の組成物。
- 前記ヒト・ベータ・ディフェンシンが、ヒト・ベータ・ディフェンシン２（配列番号２）である、請求項１〜８のいずれか一項に記載の組成物。
- 前記炎症性腸疾患がクローン病である、請求項１〜９のいずれか一項に記載の組成物。
- 前記炎症性腸疾患が潰瘍性大腸炎である、請求項１〜９のいずれか一項に記載の組成物。
- 前記治療がなされた組織中において、ＴＮＦ−アルファ活性が減少する、請求項１〜１０のいずれか一項に記載の組成物。
- 配列番号１、配列番号２、配列番号３、又は配列番号４のアミノ酸配列のいずれか一つと、少なくとも８０％、好ましくは少なくとも８５％、より好ましくは少なくとも９０％、そして最も好ましくは少なくとも９５％の同一性を有するヒト・ベータ・ディフェンシンを投与することを含む、組織においてＴＮＦ−アルファ活性を減少させる方法。
- 配列番号１、配列番号２、配列番号３、又は配列番号４のアミノ酸配列のいずれか一つと、少なくとも８０％、好ましくは少なくとも８５％、より好ましくは少なくとも９０％、そして最も好ましくは少なくとも９５％の同一性を有するヒト・ベータ・ディフェンシンを投与することを含む、組織においてＴＮＦ−アルファ活性を減少させるイン・ビトロでの方法。
- 配列番号１、配列番号２、配列番号３、又は配列番号４のアミノ酸配列のいずれか一つと、少なくとも８０％、好ましくは少なくとも８５％、より好ましくは少なくとも９０％、そして最も好ましくは少なくとも９５％の同一性を有するヒト・ベータ・ディフェンシンを投与することを含む、組織においてＩＬ−１０活性を増大させる方法。
- 配列番号１、配列番号２、配列番号３、又は配列番号４のアミノ酸配列のいずれか一つと、少なくとも８０％、好ましくは少なくとも８５％、より好ましくは少なくとも９０％、そして最も好ましくは少なくとも９５％の同一性を有するヒト・ベータ・ディフェンシンを投与することを含む、組織においてＩＬ−１０活性を増大させるイン・ビトロでの方法。
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08160761.6 | 2008-07-18 | ||
| EP08160761 | 2008-07-18 | ||
| EP08162486 | 2008-08-15 | ||
| EP08162486.8 | 2008-08-15 | ||
| EP08163614 | 2008-09-03 | ||
| EP08163614.4 | 2008-09-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517955A Division JP2011528333A (ja) | 2008-07-18 | 2009-07-17 | 哺乳動物のベータ・ディフェンシンを用いた、炎症性腸疾患の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011225596A JP2011225596A (ja) | 2011-11-10 |
| JP2011225596A5 true JP2011225596A5 (ja) | 2012-04-05 |
Family
ID=41530820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517955A Pending JP2011528333A (ja) | 2008-07-18 | 2009-07-17 | 哺乳動物のベータ・ディフェンシンを用いた、炎症性腸疾患の治療 |
| JP2011144522A Pending JP2011225596A (ja) | 2008-07-18 | 2011-06-29 | 哺乳動物のベータ・ディフェンシンを用いた、炎症性腸疾患の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517955A Pending JP2011528333A (ja) | 2008-07-18 | 2009-07-17 | 哺乳動物のベータ・ディフェンシンを用いた、炎症性腸疾患の治療 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8232242B2 (ja) |
| EP (2) | EP2399600A1 (ja) |
| JP (2) | JP2011528333A (ja) |
| KR (1) | KR20110092325A (ja) |
| CN (2) | CN102159233A (ja) |
| AP (2) | AP2011005538A0 (ja) |
| AR (2) | AR072032A1 (ja) |
| AU (1) | AU2009272681A1 (ja) |
| BR (2) | BRPI0924481A2 (ja) |
| CA (2) | CA2750727A1 (ja) |
| CL (1) | CL2011000099A1 (ja) |
| EA (2) | EA201100910A1 (ja) |
| IL (2) | IL210715A0 (ja) |
| MX (1) | MX2011000568A (ja) |
| NZ (2) | NZ593653A (ja) |
| PH (1) | PH12012501542A1 (ja) |
| SG (1) | SG172709A1 (ja) |
| TW (2) | TW201138810A (ja) |
| WO (1) | WO2010007166A2 (ja) |
| ZA (1) | ZA201100461B (ja) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2011005537A0 (en) * | 2008-07-18 | 2011-02-28 | Novozymes Adenium Biotech As | Treatment of inflammatory diseases with mammal beta defensins. |
| AP2011005538A0 (en) | 2008-07-18 | 2011-02-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins. |
| BRPI0915778A2 (pt) * | 2008-07-18 | 2019-09-24 | Novozymes Adenium Biotech As | uso de uma beta defensiva humana |
| KR101249702B1 (ko) * | 2010-06-16 | 2013-04-05 | 주식회사 나이벡 | 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| EP2696680B1 (en) | 2011-04-15 | 2018-11-28 | Marine Polymer Technologies, Inc. | Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers |
| US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
| US20130052213A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
| US10257564B2 (en) * | 2013-01-24 | 2019-04-09 | Saturn Licensing Llc | Distributed non-real-time content |
| CN104628864B (zh) * | 2013-11-14 | 2020-04-10 | 中国医学科学院医药生物技术研究所 | 一种抗肿瘤融合蛋白EL-defensin、其编码基因和用途 |
| US20190192626A1 (en) * | 2016-04-29 | 2019-06-27 | Defensin Therapeutics Aps | Treatment of liver, biliary tract and pancreatic disorders |
| SG10202012106WA (en) | 2016-12-13 | 2021-01-28 | Defensin Therapeutics Aps | Methods for treating inflammatory conditions of the lungs |
| JP2021502363A (ja) * | 2017-11-10 | 2021-01-28 | ディフェンシン セラピューティクス エーピーエス | 早期産児における粘膜抵抗力および腸／肺機能の成熟 |
| EP3713590A2 (en) | 2017-11-24 | 2020-09-30 | Defensin Therapeutics ApS | Prevention and treatment of graft-versus-host-disease with defensins |
| KR102244161B1 (ko) * | 2018-08-31 | 2021-04-26 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
| CN113684162B (zh) * | 2021-06-03 | 2024-02-27 | 江南大学 | 一种表达小鼠防御素mBD14基因的重组植物乳杆菌及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| DE4343591A1 (de) | 1993-12-21 | 1995-06-22 | Evotec Biosystems Gmbh | Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6576755B1 (en) * | 1997-09-10 | 2003-06-10 | Zymogenetics, Inc. | Beta-defensins |
| DE19957043A1 (de) * | 1999-11-26 | 2001-06-07 | Forssmann Wolf Georg | Neue Defensine |
| US7338936B2 (en) * | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| FR2841556B1 (fr) | 2002-07-01 | 2007-07-20 | Centre Nat Rech Scient | Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments |
| NZ540506A (en) | 2002-12-19 | 2008-09-26 | Yitzchak Hillman | Disease treatment via antimicrobial peptide inhibitors |
| US20070207209A1 (en) | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| GB0514482D0 (en) | 2005-07-14 | 2005-08-17 | Ares Trading Sa | Protein |
| WO2007081486A2 (en) * | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
| US8895062B2 (en) | 2006-01-24 | 2014-11-25 | University Of Maryland, Baltimore | Surface-layer protein coated microspheres and uses thereof |
| KR20100061486A (ko) | 2007-09-11 | 2010-06-07 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드의 용도 |
| AP2011005537A0 (en) | 2008-07-18 | 2011-02-28 | Novozymes Adenium Biotech As | Treatment of inflammatory diseases with mammal beta defensins. |
| AP2011005538A0 (en) | 2008-07-18 | 2011-02-28 | Novozymes Adenium Biotech As | Treatment of inflammatory bowel diseases with mammal beta defensins. |
| BRPI0915778A2 (pt) | 2008-07-18 | 2019-09-24 | Novozymes Adenium Biotech As | uso de uma beta defensiva humana |
| US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
| US20130052213A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes A/S | Novel immunomodulatory peptide |
-
2009
- 2009-07-17 AP AP2011005538A patent/AP2011005538A0/xx unknown
- 2009-07-17 US US12/504,909 patent/US8232242B2/en active Active
- 2009-07-17 AR ARP090102741A patent/AR072032A1/es not_active Application Discontinuation
- 2009-07-17 CN CN2009801363438A patent/CN102159233A/zh active Pending
- 2009-07-17 NZ NZ593653A patent/NZ593653A/xx not_active IP Right Cessation
- 2009-07-17 BR BRPI0924481-6A patent/BRPI0924481A2/pt not_active IP Right Cessation
- 2009-07-17 EA EA201100910A patent/EA201100910A1/ru unknown
- 2009-07-17 AP AP2011005755A patent/AP2011005755A0/xx unknown
- 2009-07-17 EP EP11182338A patent/EP2399600A1/en not_active Withdrawn
- 2009-07-17 CA CA2750727A patent/CA2750727A1/en not_active Abandoned
- 2009-07-17 JP JP2011517955A patent/JP2011528333A/ja active Pending
- 2009-07-17 MX MX2011000568A patent/MX2011000568A/es not_active Application Discontinuation
- 2009-07-17 EP EP09780791A patent/EP2320930A2/en not_active Withdrawn
- 2009-07-17 NZ NZ590468A patent/NZ590468A/en not_active IP Right Cessation
- 2009-07-17 SG SG2011043452A patent/SG172709A1/en unknown
- 2009-07-17 AU AU2009272681A patent/AU2009272681A1/en not_active Abandoned
- 2009-07-17 EA EA201170219A patent/EA201170219A1/ru unknown
- 2009-07-17 BR BRPI0915973-8A patent/BRPI0915973A2/pt not_active IP Right Cessation
- 2009-07-17 WO PCT/EP2009/059253 patent/WO2010007166A2/en active Application Filing
- 2009-07-17 CN CN201110163184XA patent/CN102247591A/zh active Pending
- 2009-07-17 KR KR1020117014574A patent/KR20110092325A/ko not_active Application Discontinuation
- 2009-07-17 CA CA2730789A patent/CA2730789A1/en not_active Abandoned
- 2009-07-20 TW TW100128455A patent/TW201138810A/zh unknown
- 2009-07-20 TW TW098124402A patent/TW201004640A/zh unknown
-
2011
- 2011-01-17 CL CL2011000099A patent/CL2011000099A1/es unknown
- 2011-01-18 IL IL210715A patent/IL210715A0/en unknown
- 2011-01-18 ZA ZA2011/00461A patent/ZA201100461B/en unknown
- 2011-06-13 US US13/158,638 patent/US8802621B2/en active Active
- 2011-06-16 AR ARP110102093A patent/AR081948A2/es not_active Application Discontinuation
- 2011-06-21 IL IL213680A patent/IL213680A0/en unknown
- 2011-06-29 JP JP2011144522A patent/JP2011225596A/ja active Pending
-
2012
- 2012-07-09 US US13/544,253 patent/US20120309678A1/en not_active Abandoned
- 2012-07-27 PH PH12012501542A patent/PH12012501542A1/en unknown
-
2014
- 2014-01-30 US US14/168,849 patent/US9279010B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011225596A5 (ja) | ||
| JP2011528333A5 (ja) | ||
| JP2012041342A5 (ja) | ||
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| JP2013515009A5 (ja) | ||
| JP2011241213A5 (ja) | ||
| JP2009500045A5 (ja) | ||
| NZ713202A (en) | Diagnosis and treatments relating to th2 inhibition | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| WO2009033774A3 (en) | Use of a laminin nonapeptide as a therapeutic agent | |
| WO2009033795A3 (en) | Use of a obestatin as a therapeutic agent | |
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| JP2015524444A5 (ja) | ||
| CA2730789A1 (en) | Treatment of inflammatory bowel diseases with mammal beta defensins | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| WO2009046822A3 (en) | Use of the peptide ymdgtmsqv as a therapeutic agent | |
| JP2012517478A5 (ja) | ||
| JP2019515908A5 (ja) | ||
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| WO2009040072A3 (en) | Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis | |
| JP2014513722A5 (ja) | ||
| JP2016508123A5 (ja) | ||
| JP2013541583A5 (ja) | ||
| JP2012524112A5 (ja) |